Stryker Corporation $SYK Shares Sold by Blair William & Co. IL

Blair William & Co. IL lessened its holdings in Stryker Corporation (NYSE:SYK) by 0.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 919,505 shares of the medical technology company’s stock after selling 4,752 shares during the period. Stryker makes up 0.9% of Blair William & Co. IL’s investment portfolio, making the stock its 21st largest position. Blair William & Co. IL owned 0.24% of Stryker worth $339,913,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Vanguard Group Inc. lifted its position in Stryker by 0.8% in the third quarter. Vanguard Group Inc. now owns 33,773,399 shares of the medical technology company’s stock valued at $12,485,012,000 after buying an additional 272,828 shares during the last quarter. State Street Corp increased its position in shares of Stryker by 1.0% during the second quarter. State Street Corp now owns 14,956,732 shares of the medical technology company’s stock valued at $5,929,765,000 after acquiring an additional 150,204 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Stryker by 1.1% in the 2nd quarter. Geode Capital Management LLC now owns 7,393,611 shares of the medical technology company’s stock valued at $2,910,445,000 after acquiring an additional 79,654 shares during the period. Alliancebernstein L.P. lifted its holdings in shares of Stryker by 307.6% in the 2nd quarter. Alliancebernstein L.P. now owns 5,596,508 shares of the medical technology company’s stock worth $2,214,146,000 after acquiring an additional 4,223,366 shares during the last quarter. Finally, Norges Bank acquired a new position in shares of Stryker in the 2nd quarter worth approximately $1,882,173,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Price Performance

Stryker stock opened at $364.11 on Friday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.89 and a quick ratio of 1.21. The business has a 50 day simple moving average of $365.45 and a 200-day simple moving average of $369.14. Stryker Corporation has a 12 month low of $329.16 and a 12 month high of $404.87. The stock has a market capitalization of $139.34 billion, a PE ratio of 43.35, a price-to-earnings-growth ratio of 2.16 and a beta of 0.85.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, January 29th. The medical technology company reported $4.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.40 by $0.07. Stryker had a net margin of 12.92% and a return on equity of 24.41%. The company had revenue of $7.17 billion for the quarter, compared to analysts’ expectations of $7.12 billion. During the same period in the previous year, the company posted $4.01 EPS. Stryker’s revenue was up 11.4% compared to the same quarter last year. Equities analysts predict that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 1.0%. The ex-dividend date of this dividend is Tuesday, March 31st. Stryker’s dividend payout ratio is currently 41.90%.

Insider Buying and Selling

In other Stryker news, Director Ronda E. Stryker sold 250,000 shares of Stryker stock in a transaction that occurred on Wednesday, February 4th. The stock was sold at an average price of $362.92, for a total value of $90,730,000.00. Following the sale, the director owned 2,457,331 shares of the company’s stock, valued at approximately $891,814,566.52. The trade was a 9.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.90% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the stock. Sanford C. Bernstein lifted their target price on shares of Stryker from $450.00 to $465.00 and gave the company an “outperform” rating in a report on Friday, January 9th. Citigroup restated a “market outperform” rating on shares of Stryker in a research report on Friday, January 30th. Needham & Company LLC boosted their price objective on Stryker from $448.00 to $454.00 and gave the company a “buy” rating in a report on Friday, January 30th. Wells Fargo & Company increased their target price on Stryker from $452.00 to $456.00 and gave the stock an “overweight” rating in a research note on Friday, November 14th. Finally, Royal Bank Of Canada restated an “outperform” rating and set a $435.00 target price on shares of Stryker in a report on Friday, November 14th. Fourteen research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to MarketBeat, Stryker presently has a consensus rating of “Moderate Buy” and a consensus target price of $428.61.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.